Showing results (51-60 of 62) with videos related to
Sort By:
Pageof 7
Therapeutic Innovation & Regulatory Science|September 22, 2018
Coalition Against Major Diseases: Precompetitive Collaborations and Regulatory Paths to Accelerating Drug Development for Neurodegenerative DiseasesDiane Stephenson, Enrique Aviles, Lisa J Bain, et al.Expert Review of Neurotherapeutics|February 25, 2015
Building a roadmap for developing combination therapies for Alzheimer's diseaseDaniel Perry, Reisa Sperling, Russell Katz, et al.Journal of Pharmacokinetics and Pharmacodynamics|October 8, 2014
Modeling and simulation for medical product development and evaluation: highlights from the FDA-C-Path-ISOP 2013 workshopKlaus Romero, Vikram Sinha, Sandra Allerheiligen, et al.Journal of Parkinson'S Disease|September 26, 2015
Precompetitive Data Sharing as a Catalyst to Address Unmet Needs in Parkinson's DiseaseDiane Stephenson, Michele T Hu, Klaus Romero, et al.Clinical Pharmacology and Therapeutics|April 24, 2021
A Disease Progression Model to Quantify the Nonmotor Symptoms of Parkinson's Disease in Participants With Leucine-Rich Repeat Kinase 2 MutationMalidi Ahamadi, Nitin Mehrotra, Nathan Hanan, et al.Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 3, 2014
Coalition Against Major Diseases/European Medicines Agency biomarker qualification of hippocampal volume for enrichment of clinical trials in predementia stages of Alzheimer's diseaseDerek L G Hill, Adam J Schwarz, Maria Isaac, et al.The Lancet. Neurology|January 24, 2024
A biological definition of neuronal α-synuclein disease: towards an integrated staging system for researchTanya Simuni, Lana M Chahine, Kathleen Poston, et al.NPJ Parkinson'S Disease|September 27, 2024
Neuronal alpha-Synuclein Disease integrated staging system performance in PPMI, PASADENA, and SPARK baseline cohortsTien Dam, Gennaro Pagano, Michael C Brumm, et al.Medrxiv : the Preprint Server for Health Sciences|September 24, 2024
Neuronal alpha-Synuclein Disease Integrated Staging System performance in PPMI, PASADENA, and SPARK baseline cohortsTien Dam, Gennaro Pagano, Michael C Brumm, et al.NPJ Parkinson'S Disease|November 20, 2024
Accelerating Parkinson's Disease drug development with federated learning approachesAmit Khanna, Jamie Adams, Chrystalina Antoniades, et al.Pageof 7